|
|
|
Volumn 57, Issue 3, 2003, Pages 175-179
|
|
An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (gaviscon advance®) in the treatment of heartburn during pregnancy
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GAVISCON;
GAVISCON ADVANCE;
LIQUID GAVISCON;
ADULT;
ANTEPARTUM HEMORRHAGE;
ARTICLE;
CESAREAN SECTION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG MECHANISM;
DRUG SAFETY;
ECLAMPSIA;
FEMALE;
FETUS DISTRESS;
GENERAL PRACTICE;
GESTATION PERIOD;
HEARTBURN;
HUMAN;
MAJOR CLINICAL STUDY;
MATERNAL HYPERTENSION;
MATERNAL MORTALITY;
MULTICENTER STUDY;
NEWBORN DISEASE;
OUTCOMES RESEARCH;
PERINATAL MORTALITY;
PHASE 4 CLINICAL TRIAL;
PREGNANCY DISORDER;
PREMATURE LABOR;
PRENATAL CARE;
PRIORITY JOURNAL;
RATING SCALE;
SOLUTIO PLACENTAE;
SOUTH AFRICA;
SYMPTOMATOLOGY;
UNITED KINGDOM;
VAGINAL DELIVERY;
ADOLESCENT;
ADULT;
ALGINATES;
ALUMINUM HYDROXIDE;
ANTACIDS;
DRUG COMBINATIONS;
FEMALE;
GASTROESOPHAGEAL REFLUX;
HEARTBURN;
HUMANS;
PATIENT SATISFACTION;
PREGNANCY;
PREGNANCY COMPLICATIONS;
SILICIC ACID;
SODIUM BICARBONATE;
TREATMENT OUTCOME;
|
|
EID: 0037399008
PISSN: 13685031
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (45)
|
|
References (10)
|
